TY - JOUR
T1 - Quality of life after sipuleucel-t therapy
T2 - Results from a randomized, double-blind study in patients with androgen-dependent prostate cancer
AU - Beer, Tomasz M.
AU - Schellhammer, Paul F.
AU - Corman, John M.
AU - Glodé, L. Michael
AU - Hall, Simon J.
AU - Whitmore, James B.
AU - Frohlich, Mark W.
AU - Penson, David F.
N1 - Funding Information:
Funding Support: Financial and material support for this research and the manuscript was provided by Dendreon Corporation .
PY - 2013/8
Y1 - 2013/8
N2 - Objective: To collect and analyze quality-of-life (QOL) data from PROvenge Treatment and Early Cancer Treatment trial (PROTECT, NCT00779402), a phase III, randomized controlled trial of sipuleucel-T in patients with asymptomatic androgen-dependent prostate cancer. Methods: Patients experiencing prostate-specific antigen relapse after radical prostatectomy entered a 3- to 4-month run-in phase of androgen-deprivation therapy (ADT), followed by 2:1 randomization to sipuleucel-T or control. QOL was assessed throughout the run-in and 26-week post-randomization phases using the Brief Fatigue Inventory (BFI), Linear Analog Self-Assessment (LASA) scale, Global Rating of Change (GRoC) scale, and an elicited symptoms list. Results: One hundred seventy-six patients were randomized into 2 groups, the sipuleucel-T group (n = 117) or the control group (n = 59). The sample provided 80% power to detect a difference in fatigue interference score between treatment arms of 0.9 points. QOL declined predictably during ADT. At week 26, 26.2% of sipuleucel-T-treated patients and 21.6% of control-treated patients (P =.68) reported fatigue in the previous week, and the mean score for fatigue interference in the past 24 hours was 0.9 for both arms (P =.88). Results were comparable for usual fatigue (P =.91) and worst fatigue (P >.99). Mean LASA scores decreased in both groups (P =.26). The proportion of patients reporting better overall QOL on GRoC was similar (P =.62). Conclusion: There is no clinically significant negative impact on QOL after sipuleucel-T treatment compared with control after a period of ADT in patients with asymptomatic androgen-dependent prostate cancer.
AB - Objective: To collect and analyze quality-of-life (QOL) data from PROvenge Treatment and Early Cancer Treatment trial (PROTECT, NCT00779402), a phase III, randomized controlled trial of sipuleucel-T in patients with asymptomatic androgen-dependent prostate cancer. Methods: Patients experiencing prostate-specific antigen relapse after radical prostatectomy entered a 3- to 4-month run-in phase of androgen-deprivation therapy (ADT), followed by 2:1 randomization to sipuleucel-T or control. QOL was assessed throughout the run-in and 26-week post-randomization phases using the Brief Fatigue Inventory (BFI), Linear Analog Self-Assessment (LASA) scale, Global Rating of Change (GRoC) scale, and an elicited symptoms list. Results: One hundred seventy-six patients were randomized into 2 groups, the sipuleucel-T group (n = 117) or the control group (n = 59). The sample provided 80% power to detect a difference in fatigue interference score between treatment arms of 0.9 points. QOL declined predictably during ADT. At week 26, 26.2% of sipuleucel-T-treated patients and 21.6% of control-treated patients (P =.68) reported fatigue in the previous week, and the mean score for fatigue interference in the past 24 hours was 0.9 for both arms (P =.88). Results were comparable for usual fatigue (P =.91) and worst fatigue (P >.99). Mean LASA scores decreased in both groups (P =.26). The proportion of patients reporting better overall QOL on GRoC was similar (P =.62). Conclusion: There is no clinically significant negative impact on QOL after sipuleucel-T treatment compared with control after a period of ADT in patients with asymptomatic androgen-dependent prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=84880866528&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880866528&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2013.04.049
DO - 10.1016/j.urology.2013.04.049
M3 - Article
C2 - 23896100
AN - SCOPUS:84880866528
SN - 0090-4295
VL - 82
SP - 410
EP - 415
JO - Urology
JF - Urology
IS - 2
ER -